6-K
Evotec SE (EVO)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TORULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2024
COMMISSION FILE NUMBER 001-34041
EvotecSE(Translation of registrant’s name into English)
Essener Bogen 7
22419 Hamburg
Germany
Tel:+49 40 560810(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On November 22, 2024, Evotec SE (the “Company”) issued an Ad hoc announcement. A copy of the Ad hoc announcement is attached as Exhibit 99.1 hereto.
EXHIBIT INDEX
| Exhibit | Description of Exhibit |
|---|---|
| 99.1 | Comment on withdrawn non-binding offer |
SIGNATURE
Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Evotec SE | |||
|---|---|---|---|
| By: | /s/<br> Christian Wojczewski | ||
| Name: | Christian Wojczewski | ||
| Title: | Chief Executive Officer | ||
| Date: November 22, 2024 |
Exhibit 99.1
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
Ad hoc: Comment on withdrawn non-binding offer
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO)
Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for EUR11.00 per share in cash.
The Management Board and Supervisory Board of Evotec, together with its advisors, have been in the process of thoroughly assessing the Non-Binding Proposal submitted by Halozyme in a letter dated 13 November 2024, in which it expressed an interest in a combination of Halozyme with Evotec.
The Management Board and Supervisory Board continue to have strong conviction in the Company’s standalone strategy, which is expected to accelerate growth, strengthen the long-term profitability of the Company and deliver significant value to shareholders.
– End of the ad hoc release –
Contact: Volker Braun, EVP Head of Global Investor Relations &ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 1940 5058 (m), [email protected]